Figure 7.

The role of RhoA in sustained adenosine-induced EC barrier dysfunction. (a) PAECs were treated with vehicle (V) or 50 μM adenosine (A) in the absence or presence of 50 μM deoxycoformicin (D) for the indicated times. Active RhoA was assessed by pull-down assay using RBD-GST beads, which bind to GTP-RhoA. Total RhoA in the lysates was evaluated. Data represent three independent experiments. (b) PAECs were treated with vehicle (V) or 50 μM adenosine (A) plus 50 μM deoxycoformicin (D) in the absence or presence of the Rho kinase inhibitor Y27632 (10 μM) for the indicated times, and endothelial permeability was assessed by ECIS. Arrow indicates the time for addition of treatments (n = 4). *P < 0.05 versus vehicle. ^ΦP < 0.05 versus A+D.